Flyer: DSM-5 Core titles from American Psychiatric Publishing

Flyer: DSM-5 Core titles from American Psychiatric Publishing

Post #211 Shortlink: http://wp.me/pKrrB-2×5

The third stakeholder review and comment period on proposals for revisions to categories and criteria for the next edition of the Diagnostic and Statistical Manual of Mental Disorders, to be known as DSM-5, was launched on May 4.

Following closure of this final public review, revisions made by the DSM-5 Work Groups to criteria and disorder descriptions subsequent to June 15 are subject to embargo.

Final criteria sets and accompanying texts won’t be released until the DSM-5 is published, next year.

The release of DSM-5 is slated for May 18-22, 2013, during the APA’s 2013 Annual Meeting in San Francisco, CA.

A couple of days ago, the third draft was removed in its entirety from the DSM-5 Development website.

In advance of release of DSM-5, the publishing arm of the American Psychiatric Association has issued a promotional flyer for its DSM-5 CORE TITLES:

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

American Psychiatric Association

Desk Reference to the Diagnostic Criteria from DSM-5

American Psychiatric Association

DSM-5 Clinical Cases

John W. Barnhill, M.D., David J. Kupfer, M.D., and Darrel A. Regier, M.D., M.P.H.

DSM-5 Guidebook

Donald W. Black, M.D., and Jon E. Grant, M.D., M.P.H., J.D.

Study Guide to DSM-5

Laura Weiss Roberts, M.D., M.A.

DSM-5 Handbook of Differential Diagnosis

Michael B. First, M.D.

DSM-5 Self-Exam Questions

Test Questions for the Diagnostic Criteria

Philip R. Muskin, M.D.

Note that the flyer states:

• New disorders include, but are not limited to, somatic symptom disorder, hoarding disorder, mild and major neurocognitive disorder, anxiety illness disorder, and premenstrual dysphoric disorder…

According to DSM-5 draft three, the proposed name for the disorder that replaces “Hypochondriasis” in DSM-IV is intended to be “J01 Illness Anxiety Disorder” not “anxiety illness disorder,” as the flyer has it. It is to be hoped that proofs of the manual will be subject to closer scrutiny than this flyer evidently underwent.

The flyer can be opened here 

   DSM-5 flyer

or download here http://dsm5.org/SiteCollectionDocuments/AH1259%20DSM-5%20flyer.pdf

+++

Related material

Further DSM-5 spin-jobs:

Psychiatric News | November 16, 2012

Volume 47 Number 22 page 1b-10

Professional News

Results of DSM Field Trials Available on AJP in Advance

Mark Moran

The field trials provide new data for the ongoing review of proposed diagnostic criteria for DSM-5

Three papers discussing the results of the DSM-5 field trials were posted October 30 by AJP in Advance. These papers describe the methods and results of the 23 diagnoses that were assessed…

and from Task Force Chair, David J. Kupfer…

Huffington Post Blog

David J. Kupfer, MD | Chair, DSM-5 Task Force | November 7, 2012

Field Trial Results Guide DSM Recommendations

Written with Helena C. Kraemer, Ph.D.

Two years ago this month, APA announced the start of field trials that would subject proposed diagnostic criteria for the future DSM-5 to rigorous, empirically sound evaluation across diverse clinical settings. And now, as the first comprehensive analyses of that effort are published, what’s clear is just how well the field trials did their job…

For comment see:

1 Boring Old Man

OMG!…

1 Boring Old Man | November 9, 2012

Side Effects

From quirky to serious, trends in psychology and psychiatry

by Christopher Lane, Ph.D.

The DSM-5 Field Trials’ Decidedly Mixed Results

Far from being a ringing endorsement, the field trials set off fresh alarm bells

Christopher Lane, Ph.D. | November 11, 2012

“What’s the chance that a second, equally expert diagnosis will agree with the first, making a particular diagnosis reliable?” asks David Kupfer, chair of the DSM-5 task force, of the decidedly mixed results of the DSM-5 field trials. First off, are you sure you really want to know?…

You Can’t Turn a Sow’s Ear Into a Silk Purse

By Allen Frances, MD | November 11, 2012

also here on Psychiatric Times (registration required):

http://www.psychiatrictimes.com/blog/frances/content/article/10168/2113993

American Psychiatric Association Annual Meeting: May 18-22, 2013, San Francisco

American Psychiatric Association 166th Annual Meeting: May 18-22, 2013, San Francisco, CA

Post #209 Shortlink: http://wp.me/pKrrB-2wB

The American Psychiatric Association (APA) has announced its 166th Annual Meeting, scheduled for May 18-22, 2013, San Francisco, CA.

REGISTRATION DATES

EARLY BIRD REGISTRATON

Member November 1, 2012 – January 24, 2013

Nonmember November 15, 2012 – January 24, 2013

ADVANCE REGISTRATION January 25 – April 19, 2013

ONSITE REGISTRATION April 20 – May 22, 2013

Meeting website

Scientific Program

Annual Meeting Information Guide   [9MB PDF at foot of this page]

Program Highlights Preview

(Described as roughly half of the scientific program with the full program to be posted when scheduling is complete) [Click on the image at foot of page to load 9 MB PDF or download PDF from this link PREVIEW]

The DSM-5 Track starts on Page 12 of the PDF. 

 

It is planned that the DSM-5 will be released at this meeting

APA President’s Message on DSM-5  [Video 5:52 mins]

APA President Dilip Jeste, MD discusses the final stages of DSM-5 development.

Important changes to DSM-5 Development website: Draft proposals and criteria removed

Important changes to DSM-5 Development website: Draft proposals and criteria removed

Post #208 Shortlink: http://wp.me/pKrrB-2wk

Update: November 16: Webpages on the DSM-5 Development site that were no longer accessible, yesterday, via the home page or a Proposals tab menu but were still accessible via their URLs have today been placed behind a log  in.

Following closure of the third and final DSM-5 stakeholder review, revisions made by the 13 Work Groups and Task Force to proposals and criteria for DSM-5 subsequent to June 15 are subject to embargo.

You can read the DSM-5 Permissions Policy here  (Updated: 5/30/2012).

The DSM-5 Development site Terms and Conditions of Use can be read here (Effective Date: June 21, 20120).

The Terms and Conditions of Use page has not been updated to reflect very recent changes to the website.

+++

Removal of proposals for DSM-5 categories and criteria

I have a webpage change detection service set up for the home page and selected pages of the DSM-5 Development site.

Today, November 15, I was notified that the DSM-5 Development home page text has been recently edited.

The home page text has been revised and the 20 links towards the foot of the home page text to Proposed Revisions have been removed, as has the drop-down tab menu for Proposed Revisions, Rationales, Severity Specifiers for the 20 DSM-5 category sections.

The revised home text can be read here.

The home page text as it had stood prior to recent editing can be reviewed (for a while) on this Google cache page.

[…Google’s cache of http://www.dsm5.org/ . It is a snapshot of the page as it appeared on 4 Nov 2012 21:50:47 GMT…]

The DSM manual and its clinical and research criteria sets are a major cash cow for the publishing arm of the APA.

APA is protecting its intellectual property rights by removing draft criteria as they had stood at June 15, 2012 and in placing an embargo on interim revisions to the texts, prior to publication of the final categories, criteria sets and associated textual content, next year.

Consequently, draft proposals, criteria, rationales, severity specifiers and for some categories, PDF files expanding on proposals and rationales, as they had stood at the time of the third draft, are no longer available for review or for comparison with earlier iterations of the draft directly from links on the site’s home page text or from links in a Proposals tab drop-down menu along the top of the home page.

According to the DSM-5 Development home page and recent commentary from Task Force Chair, David J Kupfer, MD, DSM-5 remains on target for release in May 2013.

No recent projections for the date by which an online version of the DSM-5 is expected to be available, post publication of the print edition, have come to my attention but it is anticipated that access to any online version of the manual would be available via subscription – not as a freely accessible public domain version, as ICD-10-CM and ICD-11 will be when they are published and implemented.

DSM-5 Round up: November #1

DSM-5 Round up: November #1

Post #207 Shortlink: http://wp.me/pKrrB-2vW

Huffington Post Blog

David J. Kupfer, MD | Chair, DSM-5 Task Force | November 7, 2012

Field Trial Results Guide DSM Recommendations

Written with Helena C. Kraemer, Ph.D.

Two years ago this month, APA announced the start of field trials that would subject proposed diagnostic criteria for the future DSM-5 to rigorous, empirically sound evaluation across diverse clinical settings. And now, as the first comprehensive analyses of that effort are published, what’s clear is just how well the field trials did their job…

Full commentary

1 Boring Old Man

OMG!…

1 Boring Old Man | November 9, 2012

Side Effects

From quirky to serious, trends in psychology and psychiatry

by Christopher Lane, Ph.D.

The DSM-5 Field Trials’ Decidedly Mixed Results

Far from being a ringing endorsement, the field trials set off fresh alarm bells

Christopher Lane, Ph.D. | November 11, 2012

“What’s the chance that a second, equally expert diagnosis will agree with the first, making a particular diagnosis reliable?” asks David Kupfer, chair of the DSM-5 task force, of the decidedly mixed results of the DSM-5 field trials. First off, are you sure you really want to know?…

Full commentary

http://www.psychologytoday.com/blog/dsm5-in-distress/201211/you-cant-turn-sows-ear-silk-purse

also here on Psychiatric Times (registration required):

http://www.psychiatrictimes.com/blog/frances/content/article/10168/2113993

You Can’t Turn a Sow’s Ear Into a Silk Purse

By Allen Frances, MD | November 11, 2012

In his recent Huffington Post piece titled Field Trial Results Guide DSM Recommendations,1 DSM-5 Task Force Chair Dr David Kupfer says, “What’s clear is just how well the field trials did their job.” This surprisingly optimistic claim has inspired these telling rejoinders from Mickey Nardo, MD, and Barney Carroll, MD, 2 of the best informed critics of DSM-5.

Dr Nardo first: “The absence of biological tests in psychiatry is unique in medicine and sentences the classification of mental disorders to endless controversy. In the 1970s, Dr Robert Spitzer proposed we use inter-rater reliability as a stand in for objective tests. His statistician colleagues developed a simple measure (called ‘kappa’) to indicate the level of diagnostic agreement corrected for chance. In 1974, Spitzer reported on 5 studies that clearly exposed the unreliability of DSM-II, the official diagnostic system at the time.

“To correct this problem and obtain the diagnostic agreement necessary for research studies, Spitzer then set about constructing sets of diagnostic criteria meant to tap overt signs and symptoms, rather than the more inferential mechanisms that informed DSM-II. He also developed structured clinical interviews that provided a uniform method of assessment. These approaches worked well to improve the poor kappas obtained using the free form approach of DSM-II.

“In 1980, Spitzer took the next big step of introducing the criterion based method of diagnosis into DSM-III. What had originated as a research tool now informed all clinical practice. It was an important milestone for psychiatry when DSM-III field testing showed that the system achieved good kappas. The new manual was an instant success throughout the mental health professions and brought a measure of objectivity to a field previously dominated by warring subjective opinions. Later, in 1994, DSM-IV was also able to demonstrate good kappas in its much more extensive field testing.

“The DSM-5 Task Force originally planned two sets of field trials, the second of which was meant to provide quality control to correct whatever weaknesses would be exposed in the first. But along the way, the field testing got far behind its schedule and the quality control step was quietly cancelled. No explanation was ever offered, but it seemed likely that DSM-5 was being rushed to press so that APA could reap publishing profits.

“Dr David Kupfer now wants us to believe that the recently published results of the DSM-5 field testing somehow serve to justify the inclusion in DSM 5 of extremely controversial and much feared changes. This is a terribly misleading claim. Independent of all the other criticisms of DSM-5 (and there are plenty), the poor results of the field trials must have been a major disappointment to the Task Force. Dr Kupfer is now making a desperate attempt to salvage the failed project by putting an unrealistically positive spin on its results.

“Our forty-year experience in reliability testing for DSM-II, the RDC, DSM-III, and DSM-IV makes clear what are acceptable and what are unacceptable kappa levels. There is no way of avoiding or cloaking the stark and troubling fact that the DSM-5 field trials produced remarkably low kappas—harking back to the bad old days of DSM-II.

[see http://1boringoldman.com/index.php/2012/10/31/humility-2/ ].

“Equally disturbing, three of the eight diagnoses tested at multiple centers had widely divergent kappa values at the different sites—hardly a vote for their reliability. Even worse, two major diagnostic categories [Major Depressive Disorder and Generalized Anxiety Disorder] performed terribly, in a range that is clearly unacceptable by anybody’s standard.

[see http://1boringoldman.com/index.php/2012/10/31/but-this-is-ridiculous/ ].

“Dr Kupfer has been forced to drastically lower our expectations in an effort to somehow justify the remarkably poor and scattered DSM-5 kappa results. There is, in fact, only one possible explanation for the results—the DSM-5 field trials were poorly designed and incompetently administered. Scientific integrity requires owning up to the defects of the study, rather than asking us to deviate from historical standards of what is considered acceptable reliability. It is not cricket to lower the target kappas after the study results fail to meet reasonable expectations.

“Diagnostic agreement is the bedrock of our system—a non-negotiable bottom line. The simple truth is that by historical standards, the DSM-5 field trials did not pass muster. Dr Kupfer can’t expect to turn this sow’s ear into a silk purse.”

Dr Carroll adds this: “The purpose of DSM-5 is to have criteria that can be used reliably across the country and around the world. The puzzling variability of results across the sites in the DSM-5 field trials is a major problem. Let’s take just one of many examples—for Bipolar I Disorder, the Mayo Clinic came in with a very good kappa value of 0.73 whereas the San Antonio site came in with a really lousy kappa of 0.27. You can’t just gloss over this gaping discrepancy by reporting a mean value. The inconsistencies across sites have nothing to do with the criteria tested—they are instead prima facie evidence of unacceptably poor execution of the study protocol. The inconsistent results prove that something clearly wasn’t right in how the study was done.

“The appropriate response is to go back to the drawing board by completing the originally planned quality control second stage of testing—rather than barreling ahead to premature publication and pretending that everything is just fine when it is not. The DSM-5 leaders have lowered the goal posts and are claiming a bogus sophistication for their field trials design as an excuse for its sloppy implementation. But a low kappa is a low kappa no matter how you try to disguise it. Dr Kupfer is putting lipstick on the pig.

“Many people experience a glazing of the eyes when the term kappa appears, but it’s really a simple idea. The kappa value tells us how far we have moved from completely random agreement (a kappa of 0) to completely perfect agreement (a kappa of 1.0). The low end of kappas that DSM-5 wants us to find acceptable are barely better than blind raters throwing random darts. If there is this much slop in the system when tested at academic centers, imagine how bad things will become in the real world of busy and less specialized clinical practice.

“Something isn’t right . . . and when something isn’t right in a matter as serious as psychiatric diagnosis the professional duty is to fix it. Having shirked this responsibility, APA deserves to fail in the business enterprise that it has made of DSM-5. If ever there was a clear conflict of interest, this is it.”

Thanks are due to Drs Nardo and Carroll. There can be no doubt that the DSM-5 Field Trials were a colossal waste of money, time, and effort. First off, they didn’t ask the most obvious and important question—What are the risks that DSM-5 will create millions of misidentified new ‘patients’ who would then be subjected to unnecessary treatment? Second, the results on the question it did ask (about diagnostic reliability) are so all over the map that they are completely uninterpretable. And to top it off, DSM-5 cancelled the quality control stage that might have cleaned up the mess.

It is almost certain that DSM-5 will be a dangerous contributor to our already existing problems of diagnostic inflation and inappropriate prescription of psychotropic drugs. The DSM-5 leadership is trying to put a brave face on its badly failed first stage of field testing and has offered no excuse or explanation for canceling its second and most crucial quality control stage. This field testing fiasco erases whatever was left of the credibility of DSM-5 and APA.

Reference

1. Kupfer DJ. Field trial results guide DSM recommendations. Huffington Post. November 7, 2012. http://www.huffingtonpost.com/david-j-kupfer-md/dsm-5_b_2083092.html . Accessed November 13, 2012.

Nature News Blog

DSM field trials inflame debate over psychiatric testing

05 Nov 2012 | 15:00 GMT | Posted by Heidi Ledford | Category: Health and medicine

As the latest revision of a key psychiatric tome nears completion, field trials of its diagnoses have prompted key changes to controversial diagnoses and sparked questions as to how such trials should be conducted…

Read on

Aging Well – News & Insight for Professionals in Geriatric Medicine

Dementia and DSM-5:

Changes, Cost, and Confusion

James Siberski, MS, CMC

Aging Well, Vol. 5 No. 6 P. 12

DSM-5 changes will require providers to learn the differences between major and minor neurocognitive disorders and to explain the differences and their significance to patients and their families.

The Diagnostic and Statistical Manual of Mental Disorders (DSM), published by the American Psychiatric Association and used for diagnosis by mental health professionals in the United States, describes symptoms for all mental disorders. Its primary components are the diagnostic classifications, diagnostic criteria sets, and descriptive texts. DSM-I was initially approved in 1951 and published the following year. Since then it has been revised several times and resulted in DSM-II in 1968, DSM-III in 1980, DSM-III-R in 1987, DSM-IV in 1994, and the current version, DSM-IV-TR, in 2000. Historically, it has been both praised and criticized…

Full article

Health Care Renewal

DOES AMERICAN PSYCHIATRY MATTER?

Bernard Carroll, MD | November 03, 2012

…What lies ahead? Stakeholders are going to vote with their feet. DSM-5 is likely to be a footnote in the history of psychiatric classification. The APA will become even less relevant than it is today, much like the American Medical Association, which now commands the loyalty of maybe 30% of U.S. physicians….

Full commentary

APA finally posts DSM-5 Field Trials online and DSM-5 Round up

APA finally posts DSM-5 Field Trials online and DSM-5 Round up

Post #206 Shortlink: http://wp.me/pKrrB-2vu

Three papers discussing the results of the DSM-5 field trials were posted online yesterday by the American Journal of Psychiatry. The papers describe the methods and results of the 23 diagnoses assessed during the field trials.

APA failed to publish field trial results during the life of the third and final public review and comment period.

Access to the abstracts is free but you will need subscriber or institution access for the full PDFs or cough up $$ for the papers. ($35 per paper for 24 hours’ access. Why have these reports not been published on the DSM-5 Development website? Many classes of stakeholder will be disenfranchised.)

The article states that criteria were tested in October 2010 through February 2012 by 279 clinicians at 11 U.S. and Canadian academic centers. A second set of data from small group practices and private practices is expected to be reported early next year (that is, after the finalized draft has gone to the publishers).

Proposed criteria are still under review and won’t be finalized until approved by APA Board of Trustees.

DSM-5 draft proposals for criteria and categories as issued for the third and final stakeholder review can be read here on the DSM-5 Development website.

Note that the draft is now frozen and criteria sets and manual texts subject to embargo until publication of the DSM-5 manual. Any revisions made by the Task Force and Work Groups since the third iteration was released in May, this year, won’t be reflected on the DSM-5 Development website.

Published yesterday in the American Journal of Psychiatry and at Psychiatry Online:

Tuesday, October 30, 2012

Full text of article:

DSM-5 Field Trials Posted Online by AJP

http://alert.psychiatricnews.org/2012/10/dsm-5-field-trials-posted-online-by-ajp.html

+++
Article 1 | October 30, 2012

Abstract: http://psychiatryonline.org/article.aspx?articleid=1387935

DSM-5 Field Trials in the United States and Canada, Part I: Study Design, Sampling Strategy, Implementation, and Analytic Approaches

Diana E. Clarke, Ph.D., M.Sc.; William E. Narrow, M.D., M.P.H.; Darrel A. Regier, M.D., M.P.H.; S. Janet Kuramoto, Ph.D., M.H.S.; David J. Kupfer, M.D.; Emily A. Kuhl, Ph.D.; Lisa Greiner, M.S.S.A.; Helena C. Kraemer, Ph.D.

Am J Psychiatry 2012;:. 10.1176/appi.ajp.2012.12070998

PDF for those with subscriber access: http://ajp.psychiatryonline.org/data/Journals/AJP/0/appi.ajp.2012.12070998.pdf

+++
Article 2 | October 30, 2012

Abstract: http://psychiatryonline.org/article.aspx?articleid=1387906

DSM-5 Field Trials in the United States and Canada, Part II: Test-Retest Reliability of Selected Categorical Diagnoses

Darrel A. Regier, M.D., M.P.H.; William E. Narrow, M.D., M.P.H.; Diana E. Clarke, Ph.D., M.Sc.; Helena C. Kraemer, Ph.D.; S. Janet Kuramoto, Ph.D., M.H.S.; Emily A. Kuhl, Ph.D.; David J. Kupfer, M.D.

Am J Psychiatry 2012;:. 10.1176/appi.ajp.2012.12070999

PDF for those with subscriber access:
http://ajp.psychiatryonline.org/data/Journals/AJP/0/appi.ajp.2012.12070999.pdf

+++
Article 3 | October 30, 2012

Abstract: http://psychiatryonline.org/article.aspx?articleid=1387907

DSM-5 Field Trials in the United States and Canada, Part III: Development and Reliability Testing of a Cross-Cutting Symptom Assessment for DSM-5

William E. Narrow, M.D., M.P.H.; Diana E. Clarke, Ph.D., M.Sc.; S. Janet Kuramoto, Ph.D., M.H.S.; Helena C. Kraemer, Ph.D.; David J. Kupfer, M.D.; Lisa Greiner, M.S.S.A.; Darrel A. Regier, M.D., M.P.H.

Am J Psychiatry 2012;:. 10.1176/appi.ajp.2012.12071000

PDF for those with subscriber access:
http://ajp.psychiatryonline.org/data/Journals/AJP/0/appi.ajp.2012.12071000.pdf

Commentaries:

DSM5 in Distress
The DSM’s impact on mental health practice and research.

by Allen Frances, M.D.

DSM 5 Field Trials Discredits APA

You can’t turn a sow’s ear into a silk purse.

…According to the authors, 14 of the 23 disorders had “very good” or “good” reliability; 6 had questionable, but ‘acceptable’ levels; and just three had “unacceptable” rates. Sounds okay until you look at the actual data and discover that the cheerful words used by the DSM 5 leaders simply don’t fit their extremely disappointing results. The paper is a classic example of Orwellian ‘newspeak’…

Allen Frances, M.D. | August 30, 2012

Read full article here

Also on Huffington Post

+++

1 Boring Old Man

finally…

1 Boring Old Man | October 30, 2012

Well, they finally published the results of the DSM-5 Field Trials. Here are the links to the abstracts and the main table of kappa values to look over…

 

DSM-5 Round up

Public Lecture St Mary’s College of Maryland

http://www.smcm.edu/calendar/events/index.php?com=detail&eID=2317

DSM-V: Social, Political, and Ethical Implications

November 2

3:00 PM – 5:00 PM

Cole Cinema, Campus Center

This presentation will describe the DSM-V, scheduled for publication in May 2013, and the controversy surrounding its development. Dr. Ancis will provide an overview of the newly proposed classification system and diagnoses.

It is imperative that those involved in using the DSM-V, or potentially impacted by the DSM, be duly informed. Questions associated with the DSM-V revision process; the empirical bases of proposed changes; social, legal, and political implications; and ethical and cultural considerations will be addressed.

Dr. Ancis will describe her involvement in a number of initiatives related to DSM-V proposals, including those of the Association of Women in Psychology and Counselors for Social Justice. She will also review concerns of major mental health organizations worldwide, such as the American Psychological Association, the American Counseling Association, and the British Psychological Society, and related divisions.

Dr. Ancis is currently a Professor of Counseling and Psychological Services at Georgia State University. She earned her Bachelors, Masters, and Ph.D from the University at Albany, State University of New York. Her major areas of interest are multicultural competency training, diversity attitudes, race and gender issues, education and career development, and legal system experiences.

Event Contact Info

Janet Kosarych-Coy

Email: jmkosarychcoy@smcm.edu

Phone: 2408954283

Website: Click to Visit

Location: Cole Cinema, Campus Center

18952 E. Fisher Rd

St. Mary’s City, MD 20686

Categories:





Psychology Today

Side Effects

From quirky to serious, trends in psychology and psychiatry

The Tranquilizer Trap The scandal over benzodiazepines gets different emphasis in the UK and U.S.

Published on October 3, 2012 by Christopher Lane, Ph.D. in Side Effects

Anti-DSM Sentiment Rises in France Why French psychiatrists and psychoanalysts are opposed to the diagnostic manual  (French Stop DSM-5 Campaign)

Published on September 28, 2012 by Christopher Lane, Ph.D. in Side Effects

New York Times

Report Sees Less Impact in New Autism Definition

By BENEDICT CAREY | Published: October 2, 2012

Proposed changes to the official diagnosis of autism will not reduce the proportion of children found to have it as steeply as many have feared, scientists reported on Tuesday, in an analysis that contradicts several previous studies…

Medscape

Medscape Medical News > Psychiatry

Controversial New Diagnosis in DSM-5 May Be Faulty

Pam Harrison | October 17, 2012

Attenuated psychosis syndrome (APS), a new and controversial diagnosis for potential inclusion in the upcoming Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is questionable, new research suggests…

DSM-5 and Employment Law

In September, Douglas Hass (Franczet Radelet) published an article Could the American Psychiatric Association Cause You Headaches? The Dangerous Interaction between the DSM-5 and Employment Law:

Abstract:

http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2153268

Since its first publication in 1952, the American Psychiatric Association’s Diagnostic and Statistical Manual (DSM) has long served not only as the primary reference for mental health disorders for medical practitioners, but also as a primary authority for the legal community…

Full text in PDF format: Hass

Research Article

http://onlinelibrary.wiley.com/doi/10.1002/da.22012/abstract

Research Article

The Effect of Draft DSM-V Criteria on Posttraumatic Stress Disorder Prevalence

Patrick S. Calhoun Ph.D.1,2,3,*,
Jeffrey S. Hertzberg B.A.3,
Angela C. Kirby M.S.3,
Michelle F. Dennis B.A.2,
Lauren P. Hair M.S.3,
Eric A. Dedert Ph.D.1,2,3,
Jean C. Beckham Ph.D.1,2,3
Article first published online: 26 OCT 2012

DOI: 10.1002/da.22012

© 2012 Wiley Periodicals, Inc.

Journal of Psychosomatic Research

November 2012 Issue, Journal of Psychosomatic Research

http://www.jpsychores.com/current

Issue: Vol 73 | No. 5 | November 2012 | Pages 325-400

http://www.jpsychores.com/article/S0022-3999(12)00225-5/abstract

Predictive validity and clinical utility of DSM-5 Somatic Symptom Disorder – Comparison with DSM-IV somatoform disorders and additional criteria for consideration

Katharina Voigt
Affiliations
Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf and Schön Klinik Hamburg-Eilbek, Hamburg, Germany

Corresponding author at: Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. Tel.: +49 40 7410 54408; fax: +49 40 7410 54975.

Eileen Wollburg
Affiliations
Schön Klinik Bad Bramstedt, Bad Bramstedt, Germany

Nina Weinmann
Affiliations
Schön Klinik Bad Bramstedt, Bad Bramstedt, Germany

Annabel Herzog
Affiliations
Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf and Schön Klinik Hamburg-Eilbek, Hamburg, Germany

Björn Meyer
Affiliations
GAIA AG, Hamburg, Germany

Gernot Langs
Affiliations
Schön Klinik Bad Bramstedt, Bad Bramstedt, Germany

Bernd Löwe
Affiliations
Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf and Schön Klinik Hamburg-Eilbek, Hamburg, Germany

Received 3 July 2012; received in revised form 29 August 2012; accepted 30 August 2012; published online 24 September 2012.

Abstract

Objective
Major changes to the diagnostic category of somatoform disorders are being proposed for DSM-5. The effect of e.g. the inclusion of psychological criteria (criterion B) on prevalence, predictive validity, and clinical utility of “Somatic Symptom Disorder” (SSD) remains unclear. A prospective study was conducted to compare current and new diagnostic approaches.

Methods
In a sample of N=456 psychosomatic inpatients (61% female, mean age=44.8±10.4years) diagnosed with somatoform, depressive and anxiety disorders, we investigated the current DSM-5 proposal (SSD) plus potential psychological criteria, somatic symptom severity, and health-related quality of life at admission and discharge.

Results
N=259 patients were diagnosed with DSM-IV somatoform disorder (56.8%). With a threshold of 6 on the Whiteley Index to assess psychological criteria, the diagnosis of SSD was similarly frequent (51.8%, N=230). However, SSD was a more frequent diagnosis when we employed the recommended threshold of one subcriterion of criterion B. Patients diagnosed with only SSD but not with DSM-IV somatoform disorder showed greater psychological impairment. Both diagnoses similarly predicted physical functioning at discharge. Bodily weakness and somatic and psychological attributions at admission were among significant predictors of physical functioning at discharge. Reduction of health anxiety, bodily weakness, and body scanning significantly predicted an improvement of physical functioning.

Conclusions
Psychological symptoms enhance predictive validity and clinical utility of DSM-5 Somatic Symptom Disorder compared to DSM-IV somatoform disorders. The SSD diagnosis identifies more psychologically impaired patients than its DSM-IV precursor. The currently suggested diagnostic threshold for criterion B might increase the disorder’s prevalence.

Keywords: Somatoform disorder, Diagnosis, Diagnostic and Statistical Manual of Mental Disorders, Classification of diseases, Validation studies as topic

Ed: Note: Between publication of the second iteration of the DSM-5 draft proposals for public review and publication of the third set of draft proposals, the SSD “B type criteria” were reduced from the requirement to meet at least two from the “B type” criteria to at least one [1].

1] http://www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx?rid=368

Somatic Symptom Disorder Criteria

Trouble with timelines (2) Might APA hold back DSM-5 in response to an October 2014 ICD-10-CM compliance date?

Trouble with timelines (2): Might APA hold back publication of DSM-5 in response to a firm October 2014 ICD-10-CM compliance date?

Post #200 Shortlink: http://wp.me/pKrrB-2sW

Update at August 17: Commentary on DSM-5 from One Boring Old Man: didn’t need to happen…

Update at August 16: Commentary on DSM-5 from One Boring Old Man: all quiet on the western front…

+++

In Trouble with timelines (1): DSM-5, ICD-10-CM, ICD-11 and ICD-11-CM, on August 10, I wrote

With no changes to the published Timeline and no intimation of further delays, I’m assuming DSM-5 remains on target.

But it’s not necessarily a given that DSM-5 will be on the bookshelves for May 2013.

Roger Peele, M.D., D.L.F.A.P.A, has been a member of the DSM-5 Task Force since 2006. From 2007- 2010, Dr Peele was APA Trustee-At-Large; since 2010, Secretary to the APA Board of Trustees.

Dr Peele maintains a website at http://rogerpeele.com/index.asp providing clinical information for Montgomery County clinicians, resources for County residents and listing some of the initiatives taken relative to the American Psychiatric Association:

http://rogerpeele.com/

Writing just a few days after HHS Secretary’s announcement of intent to postpone the compliance date for adoption of ICD-10-CM/PCS codes sets for a further year, to October 1, 2014, Dr Peele informed his readers that the proposal to delay the compliance deadline

“…reduces some of the pressures to publish DSM-5 in 2013.”

In his post of February 23, Dr Peele goes on to say that a more certain answer was expected on February 28, but that remarks at the previous day’s American College of Psychiatrists meeting suggested the timing of DSM-5 for early 2013 was still on.

This suggests to me that if HHS decides not to take forward its proposal to delay ICD-10-CM compliance until October 1, 2014 but to stick with the original compliance date of October 1, 2013, that APA will still want to get its manual out several months ahead of the ICD-10-CM compliance deadline.

In order to meet a publication date of May 2013, APA says the final manual text will need to be with the publishers by December, this year. So unless HHS announces a decision within the next few weeks, APA isn’t going to have very much time left in which to dither over potentially shifting publication to 2014.

ICD-10-CM will be freely available online and is already accessible for pre implementation viewing. It’s the policy of WHO, Geneva, to make print versions of ICD publications globally available at reasonable cost. Although ICD-10-CM has been developed by US committees for US specific use, it’s not expected that print versions of ICD-10-CM will be as expensive as DSM-5.

DSM manuals are expensive; they are a commercial product generating substantial income for the APA’s publishing arm. APA will be looking to maximize sales and publication revenue and retain market share with this forthcoming edition.

There are already groups and petitions calling for the boycotting of DSM-5 in favour of using Chapter 5 of ICD-10-CM, when its code sets are operationalized.

So if ICD-10-CM is to be adopted by October 1, 2013, I cannot see APA and American Psychiatric Publishing not aiming to steal a march.

If, on the other hand, HHS were to announce shortly a firm rule that compliance for ICD-10-CM is being pushed back to October 2014, if DSM-5 Task Force and work groups are struggling to finalize the manual or having problems obtaining approval for some of their more contentious proposals from the various panels that are scrutinizing the near final draft, then delaying publication of DSM-5 to late 2013 or spring 2014 would provide APA with a window in which to complete its manual but still push it out ahead of ICD-10-CM.

Its PR firm can sell a publication delay to end-users as the APA’s taking the opportunity of postponement of ICD-10-CM compliance to allow more time for evaluation of DSM-5 field trial results, refinement of criteria or honing disorder description texts, and that a delay will better facilitate harmonization efforts with ICD-10-CM and ICD-11.

(ICD-10-CM is a modification of the WHO’s ICD-10 and has closer correspondence with DSM-IV than with DSM-5. Since 2003, ICD-9-CM diagnostic codes have been mandated by HIPAA for all electronic reporting and transactions for third-party billing and reimbursement and DSM-5 codes will need to be crosswalked to ICD-9-CM codes, for the remaining life of the ICD-9-CM. DSM-5 codes will also need to be convertible to ICD-10-CM codes for all electronic transactions.)

In a June 2011 presentation to the International Congress of the Royal College of Psychiatrists, APA President, John M. Oldham, MD, MS, spoke of “Negotiations in progress to ‘harmonize’ DSM-5 with ICD-11 and to ‘retro-fit’ these codes into ICD-10-CM” and that DSM-5 would need “to include ICD-10-CM ‘F-codes’ in order to process all insurance claims beginning October 1, 2011.”

With the drafting timelines for the three systems now so out of whack and a partial code freeze on ICD-10-CM, and with ICD-11 still at the Beta drafting stage, I can no longer be bothered to attempt to unscramble how alignment of the three systems [or best fit where no corresponding category exists] is going to dovetail, in practice, pre and post publication, or what the implications might be for the medical billing and coding industry, for clinicians and for patients.

Dr Peele then says

“Since ICD-11-CM is due in 2016, it may become appealing to the Feds to skip ICD-10-CM, and wait until 2016”

ICD-11-CM due in 2016?

Not so. It is the WHO’s ICD-11 that is aiming for readiness by 2016.

A misconception on the part of Dr Peele or wishful thinking?

It might suit the interests of APA and American Psychiatric Publishing, financially and politically, if ICD-10-CM were to be thrown overboard and instead, the US skip to a Clinical Modification of ICD-11, two or three years after a copy of its shiny new DSM-5 is sitting on every psychiatrist’s desk.

But that is not going to happen in 2016.

There is strong federal opposition, in any case, against leapfrogging over ICD-10-CM to a US modification of ICD-11:

Federal Register, January 16, 2009:

…We [ICD-9-CM Coordination and Maintenance Committee] discussed waiting to adopt the ICD-11 code set in the August 22, 2008 proposed rule (73 FR 49805)…

…However, work cannot begin on developing the necessary U.S. clinical modification to the ICD–11 diagnosis codes or the ICD–11 companion procedure codes until ICD–11 is officially released. Development and testing of a clinical modification to ICD–11 to make it usable in the United States will take an estimated additional 5 to 6 years. We estimated that the earliest projected date to begin rulemaking for implementation of a U.S. clinical modification of ICD–11 would be the year 2020.

The suggestion that we wait and adopt ICD–11 instead of ICD–10–CM and ICD–10–PCS does not consider that the alpha-numeric structural format of ICD–11 is based on that of ICD–10, making a transition directly from ICD–9 to ICD–11 more complex and potentially more costly. Nor would waiting until we could adopt ICD–11 in place of the adopted standards address the more pressing problem of running out of space in ICD–9–CM Volume 3 to accommodate new procedure codes…

And from a more recent Federal Register document:

Federal Register, April 17, 2012:

3. Option 3: Forgo ICD-10 and Wait for ICD-11

…The option of foregoing a transition from ICD-9 to ICD-10, and instead waiting for ICD-11, was another alternative that was considered. This option was eliminated from consideration because the World Health Organization, which creates the basic version of the medical code set from which all countries create their own specialized versions, is not expected to release the basic ICD-11 medical code set until 2015 at the earliest.

From the time of that release, subject matter experts state that the transition from ICD-9 directly to ICD-11 would be more difficult for industry and it would take anywhere from 5 to 7 years for the United States to develop its own ICD-11 CM and ICD-11-PCS versions.

 

From an interview with Christopher Chute, MD, Making the Case for the ICD-10 Compliance Delay April 4, 2012, by Gabriel Perna for Healthcare Informatics:

“…Chute is also adamant that there is no possible reason or possibility that the U.S. could just skip over ICD-10 right into ICD-11. Even with his ties to ICD-11, Chute says there it’s not realistic, nor is it plausible, to have seven-to-nine more years of ICD-9 codes, while the medical industry waits for the World Health Organization to finish drafting ICD-11 and then waits for the U.S. to adapt it for its own use.”

A recent article in the JOURNAL OF AHIMA/July 2012/Volume 83, Number 7 in response to Chute et al [1] suggests the earliest the US could move onto a CM of ICD-11 might be 2025, or 13 years from now.

So, if HHS were to announce, soonish, a final rule for an October 1, 2014 ICD-10-CM compliance date, it’s not totally out of the question, in my view, that APA (who might be struggling to complete the manual for December) may extend its publication date for a second time.

 

References

1] There are important reasons for delaying implementation of the new ICD-10 coding system. Chute CG, Huff SM, Ferguson JA, Walker JM, Halamka JD. Health Aff (Millwood). 2012 Apr;31(4):836-42. Epub 2012 Mar 21 http://www.ncbi.nlm.nih.gov/pubmed/22442180  (Abstract free; Subscription or payment required for full text)